Outcome of early-stage combination treatment with favipiravir and methylprednisolone for severe COVID-19 pneumonia: A report of 11 cases
| Autor: | Tomohisa Baba, Kota Murohashi, Atsuhito Nakazawa, Shigeru Komatsu, Takafumi Yamaya, Hiroko Okabayashi, Hideya Kitamura, Takeshi Kaneko, Katsuyuki Higa, Tsuneyuki Oda, Takashi Ogura, Ryota Otoshi, Ryo Okuda, Eri Hagiwara, Akimasa Sekine, Takashi Niwa, Yozo Sato, Ryota Shintani, Tae Iwasawa, Takaaki Kitayama, Satoshi Ikeda |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Pulmonary and Respiratory Medicine
Coronavirus disease 2019 (COVID-19) Favipiravir Antiviral Agents Methylprednisolone World health Combined treatment medicine Humans Idiopathic interstitial pneumonia Stage (cooking) Oxygen saturation (medicine) SARS-CoV-2 business.industry COVID-19 medicine.disease Amides Pneumonia Treatment Outcome Editorial Pyrazines Anesthesia Autoimmune interstitial pneumonia business medicine.drug |
| Zdroj: | Respiratory Investigation |
| ISSN: | 2212-5345 |
| DOI: | 10.1016/j.resinv.2020.08.001 |
| Popis: | Although the use of corticosteroids is not recommended in the World Health Organization statement for the treatment of coronavirus disease 2019 (COVID-19), steroid therapy may be indicated for critical cases in specific situations. Here, we report the successful treatment of 11 cases of severe COVID-19 pneumonia with favipiravir and methylprednisolone. All cases were severe and patients required oxygen administration or had a blood oxygen saturation ≤93% on room air. All were treated with favipiravir and methylprednisolone, and 10 of 11 patients responded well and required no further oxygen supplementation or ventilator management. This study shows the importance of the early-stage use of a combination of favipiravir and methylprednisolone in severe cases to achieve a favorable clinical outcome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect